Stocks and Investing Stocks and Investing
Thu, October 29, 2020
Wed, October 28, 2020

Colin Bristow Initiated (SRPT) at Strong Buy and Held Target at $212 on, Oct 28th, 2020


Published on 2024-10-27 14:32:06 - WOPRAI, Colin Bristow
  Print publication without navigation


Colin Bristow of UBS, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $212 on, Oct 28th, 2020.

Colin has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 1 agrees with Colin's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Martin Auster of "Credit Suisse" Downgraded from Buy to Hold and Decreased Target to $167 on, Thursday, August 20th, 2020


These are the ratings of the 4 analyists that currently disagree with Colin


  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $190 on, Tuesday, September 15th, 2020
  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $221 on, Monday, August 31st, 2020
  • Danielle Brill of "Raymond James" Initiated at Buy and Held Target at $200 on, Tuesday, August 25th, 2020
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $182 on, Monday, August 10th, 2020
Contributing Sources